NCT03900468终止不适用
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 29
- 试验地点
- 26
- 主要终点
- Percentage Reduction in Total Seizure Frequency
研究概览
简要总结
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Focal (partial) onset seizures (based on International League Against Epilepsy (ILAE) 2017 classification) that may or may not evolve to a bilateral tonic-clonic seizure (secondary generalization). The final determination shall be made by the Investigator based on a clinical description of the seizures and previous diagnostic testing that includes, at a minimum, video EEG (inpatient or ambulatory) that captured at least one ictal event
- •Anticipated average of 6 or more focal (partial) onset seizures per month during CMM phase, with no more than 30 consecutive seizure-free days during the CMM phase
- •Refractory to at least 3 antiepileptic drugs (AEDs) due to lack of effectiveness
- •Age 18 or older at the time of enrollment
- •Willing and able to complete the diary, with or without the assistance of a caregiver, in a reliable way as assessed by the clinical staff
- •Able to use the Patient Programmer with or without the assistance of a caregiver
- •Ability of the subject or legal representative to understand and provide signed consent for participating in the study
- •Willing and available to attend visits as scheduled and to comply with the study protocol
排除标准
- •Generalized onset epilepsy type (based on International League Against Epilepsy (ILAE) 2017 classification)
- •Seizure frequency is too frequent that subject is unable to provide daily count in order to maintain a reliable seizure diary
- •Any episode of convulsive status epilepticus within the 12 months prior to the Enrollment Visit
- •Previous diagnosis of psychogenic/non-epileptic seizures within the 12 months prior to the Enrollment Visit
- •Surgical candidate for and willing to undergo resective surgery
- •Evidence of a neurological condition that is likely to progress (e.g., brain tumor, arteriovenous malformations or cavernous angiomas)
- •Diagnosed with a progressive or degenerative neurological disorder affecting the brain
- •Significant medical condition that may impact study participation in the opinion of the investigator
- •Presence of any of the following within 1 year prior to the Enrollment Visit: psychiatric illness hospitalization, suicide attempt or symptoms of psychosis (hallucinations, delusions) unrelated to an ictal state, a post-ictal state or a medication
- •Malignancy or history of malignancy within 1 year prior to the Enrollment Visit (excluding resected basal cell carcinomas)
- •Presence of implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemakers, spinal cord stimulator, RNS) or any metallic implants in the head (e.g., aneurysm clip, cochlear implant). In the case of an implanted vagus nerve stimulator (VNS), CMM study assessment collection may occur with the device implanted but may not begin until the VNS has been off for at least 30 days. The VNS generator must be explanted prior to or at the time of the DBS neurostimulator implant and the leads removed or trimmed and capped. In the case of a subject who had been previously implanted with a responsive neurostimulator (RNS) but had a full system explant, a subject cannot begin CMM study assessment collection until the RNS has been off for at least 30 days.
- •Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. This includes administration of any antiplatelet or anticoagulant medication in the 7 days prior to surgery, chronic anticoagulant use, chronic aspirin use of greater than 325 mg/day, and any participant with a history of hemorrhagic stroke
- •History of drug or alcohol abuse within the past year
- •Condition or disease that is known to require repeat magnetic resonance imaging (MRIs)
- •Currently participating, or plans to participate, in another investigational study unless written approval is provided by the Medtronic study team
- •Implant Criteria
- •Experienced an average of 6 or more focal (partial) onset seizures per month during CMM phase, with no more than 30 consecutive seizure-free days (all seizure types)
- •Completed a qualifying baseline diary. A qualifying baseline diary meets at least one the following criteria: 1) a study diary with at least 28 completed days; 2) a pre-existing diary with at least 70 completed days.
- •Completed 3-month CMM visit
- •No suicide attempt or other self-harm behaviors within past year (assessed by Columbia Suicide Severity Rating Scale (C-SSRS) at 3-month CMM Visit)
- •For female subjects of child-bearing potential, has negative pregnancy test and if sexually active continues using reliable form of birth control.
研究组 & 干预措施
Active Deep Brain Stimulation (DBS)
Experimental
干预措施: Activa™ PC and Percept™ PC Neurostimulation Systems (Device)
结局指标
主要结局
Percentage Reduction in Total Seizure Frequency
时间窗: Pre-implant compared to 36 months post-implant
The percentage of total seizure frequency reduction will be assessed using the participant seizure diaries to demonstrate DBS therapy effectiveness
次要结局
- Percentage Reduction in Total Disabling Seizure Frequency(Pre-implant compared to 12 months post-implant)
- Percentage Reduction in Total Seizure Frequency(Pre-implant compared to 12 months post-implant)
- Percentage Reduction in Temporal Lobe Originated Seizure Frequency(Pre-implant compared to 12 months post-implant)
- SUDEP Rate Characterization(Implant to 36 months post-implant)
研究者
研究点 (26)
Loading locations...
相似试验
已完成
不适用
Deep Brain Stimulation for the Treatment of Alzheimer's DiseaseAlzheimer's DiseaseNCT01559220Ali Rezai, MD3
Unknown
不适用
Deep Brain Stimulation Follow-up After 10 YearsParkinson's DiseaseNCT01575132University of Aarhus15
已完成
不适用
Deep Brain Stimulation for the Treatment of ObesityObesityNCT01512134Ali Rezai, MD3
已完成
不适用
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease StudyParkinson's DiseaseNCT01352819Abbott Medical Devices21
招募中
1 期
DBS for DepressionTreatment Resistant DepressionNCT06096207Northwell Health20